{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:46Z","timestamp":1790920546791,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively measured CAR T-cell kinetics in peripheral blood of 92 patients with B-cell malignancies using multicolor flow cytometry. To explore underlying mechanisms, we developed a mechanistic model of CAR T-cell and tumor cell interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We captured four phases of CAR T-cell kinetics in peripheral blood: distribution, expansion, contraction, and persistence. Patients with weak expansion or deep contraction are more likely to relapse. When fitted to the 46 patients with suDicient data points, the model reproduces individual CAR T-cell kinetics but fails to predict outcomes using uniform tumor parameters. We demonstrate that identical CAR T-cell dynamics may result from diDerent tumor features, including growth rate, initial burden, or antigen density. Accurately estimating these tumor-specific factors may improve relapse prediction, while common surrogates like blood lactate dehydrogenase, International Prognostic Index score, or Ann-Arbor stage do not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that CAR T-cell kinetics within the first month can serve as early prognostic markers. Integrating tumor burden estimates is required to reconcile kinetics with individual outcomes and may, upon prospective validation, further improve risk stratification in patients with B-cell malignancies receiving CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1927857","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:37:45Z","timestamp":1790919465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Jonas","family":"Schadt","sequence":"first","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Alexander","family":"R\u00f6hnert","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Matthiensen","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Oelschl\u00e4gel","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics and Biometry (IMB), Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur C\u00e9sar","family":"Fassoni","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics and Biometry (IMB), Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology","place":["Dresden, Germany"]},{"name":"Instituto de Matem\u00e1tica e Computa\u00e7\u00e3o, Universidade Federal de Itajub\u00e1","place":["Itajub\u00e1, Minas Gerais, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6288\u2013","DOI":"10.1182\/blood-2023-174916","article-title":"Systematic literature review to identify influencing factors of efficacy and safety outcomes of chimeric antigen receptor T-cell therapies in large B-cell lymphoma","volume":"142","author":"Heger","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41540-024-00435-4","article-title":"Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects","volume":"10","author":"Kara","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12636","article-title":"Quantitative systems pharmacology model of chimeric antigen receptor T\u2010cell therapy","volume":"12","author":"Hardiansyah","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115536","article-title":"Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables","volume":"14","author":"Brummer","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126371","article-title":"A mathematical description of the bone marrow dynamics during CAR T-cell therapy in B-cell childhood acute lymphoblastic leukemia","volume":"22","author":"Mart\u00ednez-Rubio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnsns.2020.105570","article-title":"CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models","volume":"94","author":"Le\u00f3n-Triana","year":"2021","journal-title":"Commun Nonlinear Sci Numer Simul"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40324-022-00305-1","article-title":"Mathematical models of leukaemia and its treatment: a review","volume":"79","author":"Chuli\u00e1n","year":"2022","journal-title":"SeMA J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1691","article-title":"Chimeric antigen receptor T cell therapies: a review of cellular kinetic-pharmacodynamic modeling approaches","author":"Chaudhury","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/cancers13112782","article-title":"Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model","volume":"13","author":"Mueller-Schoell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005360","article-title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"20210229","DOI":"10.1098\/rspb.2021.0229","article-title":"The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy","volume":"288","author":"Kimmel","year":"2021","journal-title":"Proc Biol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apm.2023.08.029","article-title":"Mechanisms of resistance to CAR-T cell immunotherapy: Insights from a mathematical model","volume":"125","author":"Santurio","year":"2024","journal-title":"Appl Math Model"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122941","article-title":"CARTmath\u2014a mathematical model of CAR-T immunotherapy in preclinical studies of hematological cancers","volume":"13","author":"Barros","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.3390\/cancers14225576","article-title":"Modeling patient-specific CAR-T cell dynamics: multiphasic kinetics via phenotypic differentiation","volume":"14","author":"Paix\u00e3o","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model\u2010based cellular kinetic analysis of chimeric antigen receptor\u2013T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2024.1380018","article-title":"A multi-scale semi-mechanistic CK\/PD model for CAR T-cell therapy","volume":"4","author":"Minucci","year":"2024","journal-title":"Front Syst Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012908","article-title":"Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome","volume":"21","author":"Santurio","year":"2025","journal-title":"PloS Comput Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jtbi.2012.12.025","article-title":"Quantifying T lymphocyte turnover","volume":"327","author":"De Boer","year":"2013","journal-title":"J Theor Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.10663-10669.2001","article-title":"Recruitment times, proliferation, and apoptosis rates during the CD8+ T-cell response to lymphocytic choriomeningitis virus","volume":"75","author":"De Boer","year":"2001","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1006\/jtbi.2003.3208","article-title":"Models of CD8+ responses: 1. What is the antigen-independent proliferation program","volume":"221","author":"Antia","year":"2003","journal-title":"J Theor Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri1550","article-title":"The role of models in understanding CD8+ T-cell memory","volume":"5","author":"Antia","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433012","article-title":"Metabolic tumor volume and the survival of patients with Non-Hodgkin lymphoma treated with chimeric antigen receptor T cell therapy: a meta-analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2561","article-title":"In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B\u2010cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158097","article-title":"Assessment of durable responses after brexucabtagene autoleucel (KTE-X19) in the ZUMA-2 study in relapsed\/refractory mantle cell lymphoma (R\/R MCL)","volume":"140","author":"Munoz","year":"2022","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01413-z","article-title":"Investigating the influence of covariates on axicabtagene ciloleucel (axi-cel) kinetics in patients with non-Hodgkin\u2019s lymphoma","volume":"63","author":"Chartier","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0564","article-title":"A validated mathematical model of cell-mediated immune response to tumor growth","volume":"65","author":"de Pillis","year":"2005","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11538-021-00869-5","article-title":"Modeling CAR T-cell therapy with patient preconditioning","volume":"83","author":"Owens","year":"2021","journal-title":"Bull Math Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2007.00951.x","article-title":"Correlation of serum IL\u20106, IL\u20108 and IL\u201010 levels with clinicopathological features and prognosis in patients with diffuse large B\u2010cell lymphoma","volume":"30","author":"Na\u010dinovi\u0107\u2010Duleti\u0107","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156289","article-title":"Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes","volume":"169","author":"Bao","year":"2023","journal-title":"Cytokine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/10428199509064927","article-title":"Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase","volume":"18","author":"Suki","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01715117","article-title":"Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin\u2019s lymphoma and a broad range of potential clinical applications","volume":"65","author":"Hallek","year":"1992","journal-title":"Ann Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00992-5","article-title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","volume":"22","author":"Bock","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:37:46Z","timestamp":1790919466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1927857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1927857"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1927857","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1927857"}}